Abstract 16626: Empagliflozin Improves Cardiovascular (CV) Outcomes Regardless of Improvement in Cardiac and Vascular Hemodynamic Markers in Type 2 Diabetes Patients at High CV Risk in EMPA-REG OUTCOME

Introduction: In EMPA-REG OUTCOME, empagliflozin (empa) significantly reduced CV death by 38% (HR 0.62; 95% CI: 0.49, 0.77) and hospitalization for heart failure and HF death by 39% (0.61 (0.47, 0....